Table 4.
Patents | Antiplatelet agents | Recommendation | Level of recommendation | Level of evidence |
---|---|---|---|---|
Antiplatelet use for secondary prophylaxis of known cardiovascular disease | Aspirin | Restart after endoscopic hemostasis | Strong | High |
Other agents (e.g. P2Y12 receptor inhibitor) | Restart after endoscopic hemostasis | Strong | Low | |
Dual antiplatelet therapy (DAPT) | Restart aspirin after endoscopic hemostasis. Early cardiology consultation for resuming the second antiplatelet agent. |
Strong | Low |